Merck’s fast-ascending kidney cancer drug hits a setback

Merck’s fast-ascending kidney cancer drug hits a setback

Welireg’s failure in first-line kidney cancer removes a blockbuster opportunity and could leave an opening for a rival drug from Arcus Biosciences, analysts said.

Merck's Welireg combo fails in first-line kidney cancer

Adding Merck’s Welireg to an existing Keytruda regimen didn’t lead to a significant improvement in newly diagnosed patients with advanced kidney cancer, Merck announced on Tuesday. The results mark a setback ...